$SMTI

Sanara MedTech Inc.

Sanara MedTech is a medical technology company that develops and commercializes products for surgical care, primarily for use in operating rooms and other sterile settings. It markets soft tissue repair and bone fusion products to surgeons at hospitals and surgical centers, primarily in the U.S. Products include CellerateRX Surgical, a hydrolyzed collagen powder for wound management; BIASURGE, a solution for surgical wound irrigation; and bone fusion products BiFORM and ALLOCYTE Plus. Its portfolio also includes TEXAGEN, ACTIGEN and FORTIFY TRG. Sanara sells through surgical specialty distributors and company representatives, and earns money primarily from sales of its surgical products. Sanara focuses exclusively on products and technologies for the surgical market after discontinuing its Tissue Health Plus post-acute wound care services operations in mid-September 2025. It also conducts research and development through its in-house team, Rochal Technologies. As of December 31, 2025, it employs 40 U.S. based field sales representatives. Sanara is headquartered in Fort Worth, Texas.

AlphAI earnings readSecond Quarter 2026 · AUG 11Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)Verdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
2

No SEC Form 4 filings for $SMTI in the last 30 days.

See all $SMTI insider activity →
Med

Sanara Medtech earnings missed by $0.20, revenue fell short of estimates

Sanara Medtech (SMTI) reported Q3 EPS of -$0.16, missing estimates by $0.20, with revenue at $28.43M, below the $29.95M consensus. Shares closed at $32.54, down 4.71% over 3 months but up 65.94% year-over-year. InvestingPro rates its financial health as 'good performance.'

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

Sanara MedTech Inc. sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company, including THP’s business software products…

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On October 6, 2026, Sanara MedTech Inc. (the “Company”) sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company (“THP”), including THP’s business software products and related intellectual property, to an unr

SMTI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SMTI (Sanara MedTech Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.

Recent SMTI coverage spans mergers & acquisitions, earnings and financial news.

What's driving SMTI

AlphAI scores every news story that mentions SMTI with an AI model for sentiment and relevance, and aggregates insider trades from Sanara MedTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SMTI

Score
$SMTIMedEarnings

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

$SMTILowM&A· $2M · completed

Sanara MedTech Inc. sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company, including THP’s business software products…

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On October 6, 2026, Sanara MedTech Inc. (the “Company”) sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company (“THP”), including THP’s business software products and related intellectual property, to an unr

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

$SMTIMedAI 8/10M&A· target · definitive

Sanara MedTech Inc., a Texas corporation, entered into an Agreement and Plan of Merger with MiMedx Group, Inc., a Florida corporation, and Mustang Merger…

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a

$SMTIMedShareholder vote

Sanara MedTech Inc. (SMTI): Submission of Matters to a Vote of Security Holders

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders Results of Special Meeting On September 30, 2026, Sanara MedTech Inc., a Texas corporation ( “Sanara”), held a special meeting of shareholders (the “Special Meeting”) to vote on the proposals described in Sanara’s def

$SMTIMedAI 8/10

Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate

Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).

Related tickers